NMRA News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NM

Mkt Cap

$90.6M

Volume

3.26M

Next Earnings

November 5th

Loading chart

NM

NMRANeumora Therapeutics, Inc. Common Stock

NMRA

Pay with—

Available Balance0.00

NM

Mkt Cap

$89.0M

Volume

3.26M

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline UpdateNeumora Therapeutics announced that its Phase 3 KOASTAL-2 and -3 studies of navacaprant failed to achieve primary endpoints for major depressive disorder treatment, leading the company to discontinue the program. The company is refocusing on three other clinical programs (NMRA-511, NMRA-898, and NMRA-215) and implementing a 35% workforce reduction to extend cash runway into Q3 2027.GlobeNewswire Inc. · Jun 15, 2026

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law FirmThe Schall Law Firm is investigating Neumora Therapeutics, Inc. (NASDAQ: NMRA) on behalf of investors for potential securities law violations. The investigation focuses on whether the company issued false or misleading statements or failed to disclose material information to investors.Benzinga · Mar 19, 2026

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026Neumora Therapeutics announced it will host a conference call on March 30, 2026, to report Q4 and full year 2025 financial results and provide a business update. The clinical-stage biopharmaceutical company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including consolidated topline readouts for KOASTAL-2 and -3 trials anticipated in Q2 2026.GlobeNewswire Inc. · Mar 16, 2026

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026Neumora Therapeutics, a clinical-stage biopharmaceutical company, announced it will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. The company highlighted its 2026 pipeline strategy with multiple clinical data readouts expected, including KOASTAL-2 and -3 trials anticipated for Q2 2026 readout. Additionally, positive Phase 1b results from NMRA-511 in Alzheimer's disease agitation showed a clinically meaningful 15.7-point reduction on the CMAI total score.GlobeNewswire Inc. · Feb 4, 2026

Top 3 Biotech Stocks Capitalizing on the AI RevolutionThree clinical-stage biotech companies are leveraging AI to advance drug discovery and treatment in areas like aging, neuroscience, and oncology, with promising platforms that use machine learning to analyze complex biological data.Investing.com · Nov 18, 2025

Neumora Therapeutics to Host Virtual R&D Day on October 27Neumora Therapeutics will host a virtual R&D Day on October 27, 2025, highlighting its pipeline of novel neurological treatments, including a potential NLRP3 inhibitor for obesity and a vasopressin receptor antagonist for Alzheimer's disease agitation.GlobeNewswire Inc. · Oct 1, 2025

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025Neumora Therapeutics is initiating a Phase 1 clinical study for NMRA-861, a novel brain disease treatment with potential best-in-class pharmacology and no observed convulsions in pre-clinical studies.GlobeNewswire Inc. · Jul 23, 2025

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861Neumora Therapeutics initiated a Phase 1 clinical study of NMRA-861, a positive allosteric modulator targeting M4 muscarinic receptors for potential schizophrenia treatment. The study aims to evaluate safety, tolerability, and pharmacokinetics in healthy adults and those with stable schizophrenia.GlobeNewswire Inc. · Jul 9, 2025

Kuehn Law Encourages Investors of Grocery Outlet Holding Corp. to Contact Law FirmKuehn Law, a shareholder litigation law firm, is investigating whether certain officers and directors of Grocery Outlet Holding Corp. (GO) breached their fiduciary duties to shareholders. The firm is also investigating Neumora Therapeutics, Inc. (NMRA) and Solaris Energy Infrastructure, Inc. (SLRS).GlobeNewswire Inc. · May 28, 2025

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law FirmKuehn Law is investigating whether officers and directors of Neumora Therapeutics, Inc. (NMRA) breached their fiduciary duties to shareholders by allegedly misrepresenting or failing to disclose information related to the company's Phase Two and Three trials for its drug Navacaprant.GlobeNewswire Inc. · May 28, 2025

to start trading

NM

NMRANeumora Therapeutics, Inc. Common Stock

NMRA

Pay with—

Available Balance0.00

Your PositionYou don't own any NMRA yet.

Related Tickers

Earnings